Navigation Links
Tysabri May Cause Liver Damage, Health Officials Say

MS drug also used to treat Crohn's disease can show injury in as little as 6 days

WEDNESDAY, Feb. 27 (HealthDay News) -- The controversial multiple sclerosis drug Tysabri can start causing liver damage within six days of the first dose, U.S. health officials said Wednesday.

In January, the U.S. Food and Drug Administration expanded the use of Tysabri to treat Crohn's disease, a chronic inflammation of the digestive tract.

The drug has also been linked with serious brain infections in multiple sclerosis patients, as well as liver damage.

When the FDA granted approval to use Tysabri for Crohn's disease, it asked the manufacturers -- Biogen Idec of Cambridge, Mass., and Elan Corp. -- to send letters to health-care providers about the potential problems with liver toxicity.

"This [the Biogen Idec letter] was part of the approval of Jan. 14," said FDA spokeswoman Rita Chappelle. "The manufacturer was going to send out a notice to health-care providers to make them aware of the potential problem."

A warning about the danger of Tysabri to the liver is already on the product label.

"FDA does not require 'Dear Doctor Letters,' but can request that a sponsor send one to inform health-care practitioners about new adverse events that are labeled," Chappelle added.

According to the letter from Biogen Idec, the drug should be stopped or discontinued if patients become jaundiced or have other evidence of liver damage.

Tysabri (natalizumab), a monoclonal antibody used to treat MS, has been under a cloud of controversy for some time. The drug works by attaching itself to white blood cells called lymphocytes and preventing them from entering the brain, where they do damage that causes the disabling symptoms of MS.

But the drug has a checkered past. It first received FDA approval in November 2004, only to be pulled from the market three months later, after several patients in clinical trials developed a rare but deadly viral infection of the brain called progressive multifocal leukoencephalopathy.

In June 2006, the FDA allowed the drug back on the market but with strict conditions. According to those revised guidelines, Tysabri can only be administered by approved doctors, at infusion sites and pharmacies that register and comply with a patient-safety program called CD Touch, designed by Biogen Idec and approved by the FDA.

More information

For more on Tysabri, visit the U.S. Food and Drug Administration.

SOURCE: Rita Chappelle, spokeswoman, U.S. Food and Drug Administration

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Stopping Tysabri May Worsen MS
2. MS Drug Tysabri Approved for Crohns Disease
3. Drug for cluster headaches may cause heart problems
4. Study Points to Cause of Vioxx Heart Risk
5. Damp, Moldy Homes May Cause Depression
6. Constipations Many Causes and Cures
7. High Co-Pays Cause Seniors to Go Without Meds
8. 13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
9. Vocal cord dysfunction may be caused by work
10. Study finds drug spending caps cause some seniors to quit taking key medicines
11. Medicare Spending Caps Cause Seniors to Stop Meds
Post Your Comments:
Related Image:
Tysabri May Cause Liver Damage, Health Officials Say
(Date:10/12/2015)... ... October 12, 2015 , ... ... secured a new corporate headquarters, located at 485 Madison Avenue, New York, NY ... and increased emphasis on cloud-based technology. , “Care to Care is a dynamic ...
(Date:10/12/2015)... ... October 12, 2015 , ... In the first known ... individuals involved in nursing research spent as much as the equivalent of four 40-hour ... a single successful National Institutes of Health (NIH) grant application for funds to conduct ...
(Date:10/12/2015)... ... October 12, 2015 , ... CMS’s just-released 2016 Medicare ... partners to assess and act on, indicating which stars measures are causing plans the ... Part D health plans should focus their efforts and how CMS intends to modify ...
(Date:10/12/2015)... ... October 12, 2015 , ... T.E.N., a technology ... evening, October 8, at the 2015 ISE® Northeast Executive Forum and Awards ... , Michael Towers, VP, executive information security officer for Allergan, was selected as ...
(Date:10/12/2015)... ... October 12, 2015 , ... On Sunday, October 18, the Sierra Regional Spine ... in support of all Washoe County students. This is the first time the institute ... Sparks Marina outlet mall outside Reno, Nevada. , The family and youth-focused event features ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Industry Trends, Technologies, Participants, and Environment" ... ) has announced the addition of ... Companion Diagnostic Market to 2019 - Strategic ...
(Date:10/12/2015)... St. Paul, Minn. , Oct. 12, 2015 /PRNewswire/ ... with it, a need to help integrate these devices ... global leader of ergonomic healthcare mounting and mobility solutions, ... Carts, its lightest cart yet, for a wide array ... StyleView S-Tablet Cart SV10 was developed exclusively for Microsoft ...
(Date:10/12/2015)... 12, 2015 ... grow at 7.2% CAGR, microscopy market growth ... focus on nanotechnology, technological advancements, and increasing ... available with ... --> Complete report on microscopy ...
Breaking Medicine Technology: